血清趋化因子16表达水平在宫颈癌诊断中的价值

摘要:目的　探讨血清趋化因子16（CXCL16）表达水平在宫颈癌诊断中的价值。方法　回顾性分析某院就诊的宫颈癌、宫颈上皮内瘤变、宫颈炎患者和健康对照患者其血清CXCL16和糖蛋白抗原125（CA125）水平，比较其诊断阳性率。结果　宫颈癌患者血清CXCL16、CA125水平明显高于宫颈上皮内瘤变、宫颈炎和健康对照组（F＝4.432，P＝0.000；F＝2.452，P＝0.027）；宫颈癌晚期患者血清CXCL16和CA125与宫颈癌早期相比显著升高（t＝18.241，12.441；P＝0.000，0.000）；宫颈癌患者、宫颈上皮内瘤变患者和宫颈炎患者血清CXCL16水平诊断阳性率分别为91.12%、13.21%和16.44%；血清CA125水平诊断阳性率分别为76.47%、56.60％和50.68%，宫颈癌患者血清CXCL16水平诊断阳性率与血清CA125水平诊断阳性率相比显著升高（χ2＝5.423，P＝0.020），宫颈内上皮瘤变和宫颈炎患者血清CXCL16水平诊断阳性率与血清CA125水平诊断阳性率相比显著降低（χ2＝17.322，8.916，P＝0.000，0.000）；宫颈癌早期、晚期血清CXCL16水平诊断阳性率为88.89%、100.00%，分别显著高于血清CA125水平诊断阳性率69.44%、81.25%（χ2＝4.126，6.621；P＝0.042，0.010）。结论　血清 CXCL16可以做为一种宫颈癌的肿瘤标志物，较为特异和准确地在临床上应用于宫颈癌的诊断。

The significance of serum CXCL16 in the diagnosis of cervical cancer

Abstract: Objective The aim of this study was to explore the significance of serum CXCL16 in the diagnosis of cervical cancer. Methods Retrospective analysis of the serum CXCL16 and CA125 levels in cervical cancer patients, cervical intraepithelial neoplasia cervicitis patients and healthy controls was performed. Measuring and comparing the serum CXCL16 and CA125 level was done and the positive rate was calculated. Results The serum CXCL16 and CA125 levels in cervical cancer patients was much higher than that in cervical intraepithelial neoplasia cervicitis patients and healthy controls (F=4.432, P=0.000; F=2.452, P=0.027). The serum CXCL16 and CA125 levels in later phase of cervical cancer was much higher than that in early phase of cervical cancer (t=18.241, 12.441; P=0.000, 0.000). The positive rates of cervical cancer patients, cervical intraepithelial neoplasia patients and cervicitis when measuring serum CXCL16 were 91.12%, 13.21% and 16.44%, respectively, while when measuring serum CA125 the positive rate were 76.47%, 56.60% and 50.68% respectively. The positive rate in cervical cancer patients when measuring serum CXCL16 was higher than serum CA125 (χ2=5.423, P=0.020). However, it was decreased in cervical intraepithelial neoplasia patients and cervicitis patients (χ2=17.322, 8.916, P=0.000, 0.000). The positive rates in the early and later phase of cervical cancer when measuring serum CXCL16 were 88.89% and 100.00% respectively and were much higher than that of serum CA125 whose positive rates were 69.44% and 81.25% respectively (χ2=4.126, 6.621; P=0.042, 0.010). Conclusion Serum CXCL16 could be used as a tumor marker for cervical cancer, leading to a more exact and specific diagnosis of the cervical cancer.